| Website | utahventures.com |
| Phone | 801 365-0262 |
| Employees | |
| Founded | 1986 |
UV Partners, established in 1986 with offices in Salt Lake City and Los Angeles, is a leading early stage private equity investment group. UV Partners helps entrepreneurs develop early-stage concepts into tomorrow’s industry-leading Information Technology and Life Science companies. The partners possess diverse but highly complementary industry and investment backgrounds. They share a hands-on approach and work collaboratively on each portfolio company over the life of an investment thereby providing each company with a broad range of resources, experience, and knowledge.
In order to maximize their contribution to each management team, they support and concentrate on market segments where their knowledge, experience, and contacts are deepest. They are focused geographically on investments in the Western US with a particular emphasis on the Intermountain West, the Pacific Northwest, Southern California, and Northern California. They encourage entrepreneurs in smaller western markets, such as Boise, Phoenix, and Albuquerque to contact them.
Their areas of expertise lie in Information Technology and the Life Sciences. Information Technology segments include software and infrastructure, communications, networking, wireless, and internet-based companies. Key Life Sciences segments include biotechnology, medical devices, and healthcare services and information systems. In all markets, they value businesses with a significant proprietary position or unique skills and knowledge. They help build companies that will lead their industries. They invest in people that have developed a track record of related accomplishments.
| Company | Date | Round | Size | Participants |
| Adapx | 4/09 | Series B | $9M | 3 |
| M-Factor | 2/09 | Unattributed | 4 | |
| Conviva | 8/08 | Series B | $20M | 3 |
| Replay Solutions | 8/08 | Series B | $11M | 2 |
| Infopia | 4/08 | Series C | $12M | 4 |
| AngioScore | 10/07 | Series E | $30M | 6 |
| Venafi | 11/06 | Series B | $11M | 2 |